Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study
Marine Drugs · 2024
DOI: 10.3390/md22040178 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Marine Drugs, 2024. Verfasst von Irene Moreno und 11 weiteren Autor:innen. Beteiligte Einrichtung: START Madrid-Centro Integral Oncológico Clara Campal (CIOCC), Hospital Universitario HM Sanchinarro, 28050 Madrid, Spain. Hauptthemen laut MEDLINE: Itraconazole, Drug Interactions, Neoplasms, Heterocyclic Compounds, 4 or More Rings. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PharmaMar S.A..
Themen: Onkologische Pflege
Abstract (Originalsprache)
This open-label, two-part, phase Ib drug–drug interaction study investigated whether the pharmacokinetic (PK) and safety profiles of lurbinectedin (LRB), a marine-derived drug, are affected by co-administration of itraconazole (ITZ), a strong CYP3A4 inhibitor, in adult patients with advanced solid tumors. In Part A, three patients were sequentially assigned to Sequence 1 (LRB 0.8 mg/m2, 1-h intravenous [IV] + ITZ 200 mg/day oral in Cycle 1 [C1] and LRB alone 3.2 mg/m2, 1 h, IV in Cycle 2 [C2]). In Part B, 11 patients were randomized (1:1) to receive either Sequence 1 (LRB at 0.9 mg/m2 + ITZ in C1 and LRB alone in C2) or Sequence 2 (LRB alone in C1 and LRB + ITZ in C2). Eleven patients were evaluable for PK analysis: three in Part A and eight in Part B (four per sequence). The systemic total exposure of LRB increased with ITZ co-administration: 15% for Cmax, area under the curve (AUC) 2.4-fold for AUC0–t and 2.7-fold for AUC0–∞. Co-administration with ITZ produced statistically significant modifications in the unbound plasma LRB PK parameters. The LRB safety profile was consistent with the toxicities described in previous studies. Co-administration with multiple doses of ITZ significantly altered LRB systemic exposure. Hence, to avoid LRB overexposure when co-administered with strong CYP3A4 inhibitors, an LRB dose reduction proportional to CL reduction should be applied.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- START Madrid-Centro Integral Oncológico Clara Campal (CIOCC), Hospital Universitario HM Sanchinarro, 28050 Madrid, Spain.
- START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain.
- PharmaMar S.A., 28770 Colmenar Viejo, Spain.
ORCID-Profile: Tatiana Hernández, Salvador Fudio, Sara Martínez, Lola Montilla, Rubin Lubomirov
Förderung
- PharmaMar S.A.
Zitieren
APA
Moreno, I., Hernández, T., Calvo, E., Fudio, S., Kahatt, C., Martínez, S., Iglesias, J. L., Calafati, R. O., Pérez-Ramos, L., Montilla, L., Zeaiter, A., & Lubomirov, R. (2024). Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study. Marine Drugs. https://doi.org/10.3390/md22040178
Vancouver
Moreno I, Hernández T, Calvo E, Fudio S, Kahatt C, Martínez S, et al. Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study. Marine Drugs. 2024. doi:10.3390/md22040178
BibTeX
@article{Moreno2024,
author = {Moreno, Irene and Hernández, Tatiana and Calvo, Emiliano and Fudio, Salvador and Kahatt, Carmen and Martínez, Sara and Iglesias, Jorge Luis and Calafati, Román Octavio and Pérez-Ramos, Laura and Montilla, Lola and Zeaiter, Ali and Lubomirov, Rubin},
title = {Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study},
journal = {Marine Drugs},
year = {2024},
doi = {10.3390/md22040178}
}
EUVIMED